ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RFL / news
HYFT (45) PLRX (34) TLPH (36) ONCY (41) ⌘ Pro Terminal →

Why RFL Stock dropped -7.41% Today — RQD Quant Desk Flash

$1.00 -7.41% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.98

Rafael Holdings Inc. (Class B) (RFL) carries a Roarable Rating of E (Strong Sell) with 16/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $52.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RFL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RFL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Rafael Holdings Inc. (Class B) (NYSE: RFL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 16/100 at a spot price of $1.00 (-7.41% 1D, market cap $52.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RFL ranks #1010 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RFL compare to HYFT and PLRX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RFL carries a Roarable E (16/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HYFT (MindWalk Holdings Corp.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $52.3M) and PLRX (Pliant Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $52.0M). Among the 5-stock peer group, RFL leads on earnings multiple (N/A) while RFL leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RFL?
▼

Per RFL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-07-31, CIK 0001713863), Rafael Holdings Inc. (Class B) generated $30.0K in revenue (-95.3% YoY), -$30.5M in net income, and -$18.9M in free cash flow against $99.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.98 (-1.52%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (16/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510016
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (3)Whales (3)SEC (3)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-19% Base Target
$4 Bull$1 Base$1 Bear
📬 FREE RFL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RFL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (16/100 Composite)
🔍 WHY RFL SCORES 16/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (44% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.9 (OVERSOLD (<32))

▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
24
Grade E$1.43-9.1% Next Q
Q2 (-2Q)
21
Grade E$1.30-6.9% Next Q
Q3 (-1Q)
19
Grade E$1.21-17.4% Next Q
Current
16
Grade E$1.00-12.7% Hist 90D α
Trajectory: E (24) → E (16)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RFL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RFL currently carries a cautious 16/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.76) and Max Pain ($1.05) forces dealer call-delta covering toward $4.16.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RFL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RFL Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
YES 18%NO 82%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why RFL Stock dropped -7.41% Today — RQD Quant Desk Flash

Rafael Holdings Inc. (Class B) (RFL) dropped -7.41% to $1.00, trading at 2% of its 52-week range ($1 – $3.96). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 2% of its 52-week range ($1 – $3.96) with RSI-14 at 26.9 (OVERSOLD (<32)).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.00 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live RFL Headlines & Catalysts
MARKET WIREYahoo Finance • 1d ago
Upcoming & Recent IPO's - IPOs Calendar

Yahoo Finance report covering Rafael Holdings Inc. (Class B) (RFL) market action, institutional positioning, and fundamental catalysts.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RFL)

  • ✓Walkthrough of RFL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RFL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.26%🛡️ HOLDING TREND SUPPORT
2026-11-04O $1.08H $1.08L $1.00C $1.00VOL 98.4K
RES: $1.51SUP: $0.80SMA50: $1.76SMA200: $1.68
$4.17$3.31$2.45$1.59$0.73RES $1.51SUP $0.80$1.002026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RFL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RFL Butterfly Map → + Track RFL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -95.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RFL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RFL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RFL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RFL)

Health Care Rank #1010 of 1015 ⚔️ HYFT vs RFL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RFL vs. HYFT, PLRX, TLPH, ONCY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Rafael Holdings Inc. (Class B) (RFL) ranks #1010 by composite RQD confidence (16/100, grade E) and #736 by equity capitalization ($52.2M). Within this direct 5-issuer industry benchmark cohort, RFL leads on earnings valuation at N/A trailing P/E, while RFL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. HYFT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with RFL at 16/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RFL ACTIVE
Rafael Holdings Inc. (Class B)
E 16/100 — — -35.0% -7.41% $52.2M Benchmark Subject
HYFT
MindWalk Holdings Corp.
D 45/100 — — — -2.65% $52.3M /hyft-vs-rfl →
PLRX
Pliant Therapeutics Inc.
E 34/100 — — -35.0% -2.29% $52.0M /plrx-vs-rfl →
TLPH
Talphera Inc.
D- 36/100 — — -35.0% -1.94% $52.4M /tlph-vs-rfl →
ONCY
Oncolytics Biotech Inc.
D- 41/100 — — -35.0% -5.97% $52.4M /oncy-vs-rfl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-07-31 • CIK 0001713863 ↗

In its most recent audited fiscal period (FY2025, filed 2025-07-31), Rafael Holdings Inc. (Class B) (RFL) reported GAAP revenue of $30.0K (-95.3% vs. FY2024 revenue of $637.0K , and -89.2% cumulative change since FY2023) , GAAP net income of -$30.5M, operating cash flow of -$18.9M, and free cash flow of -$18.9M (-138.2% YoY). On the balance sheet, RFL closed FY2025 with $99.3M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-07-31 $30.0K -$30.5M -$18.9M -$18.9M $99.3M —
FY2024 (FY) 2024-07-31 $637.0K -$34.4M -$7.8M -$7.9M $83.0M —
FY2023 (FY) 2023-07-31 $279.0K -$1.9M -$10.9M -$10.9M — —

3. RFL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RFL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Rafael Holdings Inc. (Class B) (NYSE: RFL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 16/100 at a spot price of $1.00 (-7.41% 1D, market cap $52.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, RFL ranks #1010 in composite RQD confidence.

How does RFL compare to HYFT and PLRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RFL carries a Roarable E (16/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HYFT (MindWalk Holdings Corp.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $52.3M) and PLRX (Pliant Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $52.0M). Among the 5-stock peer group, RFL leads on earnings multiple (N/A) while RFL leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RFL?

Per RFL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-07-31, CIK 0001713863), Rafael Holdings Inc. (Class B) generated $30.0K in revenue (-95.3% YoY), -$30.5M in net income, and -$18.9M in free cash flow against $99.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RFL trading relative to its 50-day, 200-day, and 52-week technical levels?

RFL last traded at $1.00 (-7.41% on volume of 98,377 shares), positioning the stock -43.18% below its 50-day simple moving average ($1.76) and -40.48% below its 200-day simple moving average ($1.68). Across its 52-week range of $1.00 to $3.96, RFL sits at the 0.0% percentile with a 14-day RSI of 26.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.13).

Direct Sub-Reports: RFL RQD Cockpit RFL 12M Forecast RFL Earnings & Move RFL Dividends & DRIP RFL Insiders & 13F RFL Whale Options RFL Profit Sankey RFL News & Why
ROARABLE RATING BRIEF • RQD 16/100 (E) ✓ SEC XBRL & RQD VERIFIED

RFL — Rafael Holdings Inc. (Class B): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-07-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Rafael Holdings Inc. (Class B) (RFL) earns a live Roarable RQD composite score of 16/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.00 (-7.41% 1D, market capitalization $52.2M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Rafael Holdings Inc. (Class B) is a NYSE-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry..1B. Per the recent news wire, the company has submitted a New Drug Application for remibetadex in Niemann, a rare-disease candidate. — describes its specific customers or detailed revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-07-31), Rafael Holdings Inc. (Class B) (RFL) reported $30.0K in annual revenue (up from $637.0K in FY2024, -95.3% YoY) and -$30.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($279.0K revenue, -$1.9M net income) through FY2025, RFL scaled operating cash flow to -$18.9M and free cash flow to -$18.9M, backed by $99.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 16/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.00 – $3.96 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector correlation data beyond the Beta of 1. A prospective investor should watch regulatory developments tied to the remibetadex NDA and the outcome of the rare-disease trial referenced in the news wire, as these are the only company-specific catalysts identified in the source material.

  • Key Question #1: Can RFL sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $30.0K and free cash flow of -$18.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is RFL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RFL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Rafael Holdings Inc. (Class B) (RFL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RFL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RFL Bull vs. Bear Conversation Board — What's Your Call at $1.00?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RFL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RFL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $1.43 (+32.4%)
📌 Pinned Debate

A rare-disease candidate, remibetadex, has reached NDA submission stage, and short interest fell 55.9% in October.

Long RFL at $1.08 targeting $1.43. A rare-disease candidate, remibetadex, has reached NDA submission stage, and short interest fell 55.9% in October.. Institutional whale score is 3/20 and the risk/reward vs. the $1.08 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@BearTrap_Alert Shorting a 3/20 institutional whale-flow stock at $1.08 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $0.82 (-24.1%)
Spot @ $1.08

ROIC of -35%, FCF yield of 0%, and an Altman Z-Score of 0.2 signal forensic balance-sheet and cash-generation risk.

Sitting on the sidelines or leaning short RFL above $1.08. ROIC of -35%, FCF yield of 0%, and an Altman Z-Score of 0.2 signal forensic balance-sheet and cash-generation risk.. Until Fundamental Cash Engine (1/20) and FCF yield (0.0%) inflect higher, upside is capped near $3.96.

LIVE TAPE